Clinical Outcome of Chemotherapy and Radiation Therapy Versus Chemotherapy, Radiation Therapy, and Multilevel Vertebroplasty or Kyphoplasty for Multiple Myeloma
Source : https://pubmed.ncbi.nlm.nih.gov/38568002/
This study found that performing kyphoplasty and vertebroplasty in addition to conventional therapy for patients with multiple myeloma resulted in enhanced morbidity and functional outcomes. [ Orthopedics . 202x;4x(x):xx-xx.].
Kyphoplasty and vertebroplasty are cement-augmented techniques that are minimally invasive for the management of osteolytic lesions and associated disabilities in patients with multiple myeloma.
Prevalence and Consequences of a Delayed Diagnosis in Multiple Myeloma: a Single Institution Experience
Source : https://pubmed.ncbi.nlm.nih.gov/38555259/
A delay in the diagnosis of MM is very frequent in México (68% of cases); despite the fact that there was a significant trend for being in earlier stages of...
Both OS and PFS were similar in the patients diagnosed before or after 3 months from the onset of symptoms.
Cytogenetic Profile in Monoclonal Gammopathy of Undetermined Significance, Smoldering and Symptomatic Multiple Myeloma: a Study of 1087 Patients With Highly Purified Plasma Cells
Source : https://www.mdpi.com/2072-6694/15/23/5690
The aim of this study was to examine the cytogenetic profiles of plasma cell neoplasms (PCNs) at various disease stages, encompassing 1087 patients with monoclonal gammopathy of undetermined significance (MGUS),...
This study demonstrated that >95% of patients exhibited ≥1 cytogenetic abnormality detected by FISH, chromosomal analysis, or both. The frequency of IGH:CCND1 rearrangement was 26% in this cohort, but with no apparent differences across race, age, or disease.
Integrating Immune Therapies for the Treatment of Multiple Myeloma
Source : https://jnccn.org/view/journals/jnccn/21/12/article-p1303.xml
Patients with relapsed or refractory multiple myeloma (RRMM) that is refractory to a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-CD38 antibody (triple-class refractory MM) have poor outcomes. Recently,...
As of September 2023, 2 BCMA-targeting CAR T-cell products, 2 BCMA-targeting BsAbs, and 1 GPRC5D-targeting BsAb, are FDA-approved for standard-of-care use in patients with RRMM who received ≥4 prior lines of therapy, including prior treatment with a proteasome inhibitor, an IMiD, and an anti-CD38 antibody.
Severe SARS-CoV-2 and Subsequent Fungal Infections After CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: a Challenging and Happy Ending Fight
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10698652/
Chimeric antigen receptor (CAR) T-cells have unveiled a promising therapeutic horizon for relapsed/refractory multiple myeloma (R/R MM).
As shown by this case, CAR T-cell recipients can be affected by a complex immune impairment exposing them to severe COVID-19 infections.